Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home
- Thursday, July 22, 2021, 7:13
- Environment
- Add a comment
DURHAM, N.C., July 22, 2021 /PRNewswire/ — Inhalon Biopharma, Inc., a clinical-stage immunotherapy company developing an inhaled “muco-trapping” antibody platform for treating a variety of acute respiratory infections, today announced it is partnering with Celltrion, Inc. to develop…
About the Author
adminasapcorp has written 41785 stories on this site.